Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 16 of 16 for “"MPS IIIB"”.

  1. Purification of human recombinant Naglu from Sf9 cells and uptake studies with MPS IIIB fibroblasts

    Mucopolysaccharidosis IIIB (MPS IIIB) is a rare, metabolic disorder that results from a deficiency in the lysosomal hydrolase, α-N-acetylglucosaminidase (Naglu). Naglu is a housekeeping enzyme involved in the degradation pathway of heparan sulfate. A deficiency in active Naglu leads to an …

    uvic Repository record for Purification of human recombinant Naglu from Sf9 cells and uptake studies with MPS IIIB fibroblasts (opens in a new tab)

  2. Development of Quantitative Tools for the Characterization and Analysis of the Blood Brain Barrier in Normal and MPS IIIB Mice

    … as the metabolic disease Mucopolysaccharidosis IIIB, have been shown to cause breaches in the BBB’s integrity, thus suggesting a possible mechanism to administer treatment around this restriction could be to utilize a specific disease’s own pathology. In order to understand the extent of BBB …

    dominican Repository record for Development of Quantitative Tools for the Characterization and Analysis of the Blood Brain Barrier in Normal and MPS IIIB Mice (opens in a new tab)

  3. Neuropathologic characterization of a canine model of mucopolysaccharidosis IIIB and additional studies in anti-inflammatory therapy and neuroinflammatory kinetics

    <p>The mucopolysaccharidoses (MPSs) are a heterogenous group of lysosomal storage diseases that are designated MPS I through MPS IX (excluding MPS V and MPS VIII) that result in deficiencies in specific lysosomal enzymes that are responsible for the stepwise degradation of glycosaminoglycans …

    iastate Repository record for Neuropathologic characterization of a canine model of mucopolysaccharidosis IIIB and additional studies in anti-inflammatory therapy and neuroinflammatory kinetics (opens in a new tab)

  4. Characterization of ocular pathology in canine models of mucopolysaccharidosis types I and IIIB with an additional study evaluating anti-inflammatory therapy

    The mucopolysaccharidoses (MPSs) are a group of rare lysosomal storage diseases (LSDs) caused by a genetic mutation affecting various enzymes responsible for the degradation and catabolism of glycosaminoglycans (GAGs). Two of the most common types of MPS are Mucopolysaccharidosis type I (MPS I; …

    iastate Repository record for Characterization of ocular pathology in canine models of mucopolysaccharidosis types I and IIIB with an additional study evaluating anti-inflammatory therapy (opens in a new tab)

  5. Effects of oral Ambroxol on neuropathological measures in the canine model of Sanfilippo Syndrome type B

    The mucopolysaccharidoses (MPSs) are a diverse group of lysosomal storage diseases, characterized by deficiencies in specific lysosomal enzymes that are responsible for the stepwise degradation of glycosaminoglycans (GAGs). MPS types I, II, III, and VII are some of the MPSs that have neurological …

    iastate Repository record for Effects of oral Ambroxol on neuropathological measures in the canine model of Sanfilippo Syndrome type B (opens in a new tab)

  6. Mucopolysaccharidosis type IIIB and GalNAc Transferase double knockout mice and additional studies in gene therapy and animal models to assess pathogenesis and therapy

    <p>The Mucopolysaccharidoses (MPSs) are a class of lysosomal storage diseases characterized by lysosomal accumulation of glycosaminoglycan (GAG). Understanding the pathogenesis of the neuropathic forms of MPS and improving treatment options for these disorders are major areas of research in the …

    iastate Repository record for Mucopolysaccharidosis type IIIB and GalNAc Transferase double knockout mice and additional studies in gene therapy and animal models to assess pathogenesis and therapy (opens in a new tab)

  7. Molecular techniques for therapeutic and diagnostic applications in Mucopolysaccharidosis IIIB and Gaucher disease

    … Gaucher disease (GD) and mucopolysaccharidosis IIIB (MPS IIIB). Mutations in NAGLU and GBA1, the genes that encode for lysosomal hydrolases required for degradation of heparan sulfate and glucocerebrosides, lead to the observed pathogenesis in MPS IIIB and GD, respectively. Since many LDs, …

    uvic Repository record for Molecular techniques for therapeutic and diagnostic applications in Mucopolysaccharidosis IIIB and Gaucher disease (opens in a new tab)

  8. Mucopolissacaridose IIIB : avaliação clínica, bioquímica e epidemiológica de pacientes brasileiros

    … tecidos corporais causam a Mucopolissacaridose IIIB, uma doença lisossomal caracterizada por manifestações principalmente neurológicas, mas em menor grau, em manifestações somáticas. Não há uma caracterização clínica completa dos pacientes com MPS IIIB diagnosticados pela Rede MPS Brasil, e tal …

    brazil-ufrgs Repository record for Mucopolissacaridose IIIB : avaliação clínica, bioquímica e epidemiológica de pacientes brasileiros (opens in a new tab)

  9. Purification and Uptake Studies of Recombinant Human N-α-D-Acetylglucosaminidase from Sf9 Insect Cells

    … disorder Mucopolysaccharidosis III type B (MPS IIIB). A deficiency in Naglu results in a buildup of heparan sulfate in lysosomes, which is most detrimental in the central nervous system, causing mental retardation and a shortened lifespan. Enzyme replacement therapy is currently ineffective …

    uvic Repository record for Purification and Uptake Studies of Recombinant Human N-α-D-Acetylglucosaminidase from Sf9 Insect Cells (opens in a new tab)

  10. Expression of human α-N-Acetylglucosaminidase in Sf9 insect cells: effect of cryptic splice site removal and native secretion-signaling peptide addition.

    … disorder known as mucopolysaccharidosis type IIIB (MPS IIIB; also Sanfilippo syndrome B). Absence of this enzyme results in cytotoxic accumulation of heparan sulphate in the central nervous system, causing mental retardation and a shortened lifespan. Enzyme replacement therapy is not currently …

    uvic Repository record for Expression of human α-N-Acetylglucosaminidase in Sf9 insect cells: effect of cryptic splice site removal and native secretion-signaling peptide addition. (opens in a new tab)

  11. The expression of α-N-acetylglucosaminidase in the methylotrophic yeast Pichia pastoris

    Mucopolysaccharidosis IIIB (MPS IIIB) is an autosomal recessive disorder of glycosaminoglycan (GAG) metabolism. Disruption of the gene encoding a-N-acetylglucosaminidase (Naglu) results in the inability to degrade the GAG heparan sulfate (HS). Consequently. undegraded HS builds up and results in …

    uvic Repository record for The expression of α-N-acetylglucosaminidase in the methylotrophic yeast Pichia pastoris (opens in a new tab)

  12. The expression of alpha-N-acetylglucosaminidase in two heterologous gene expression systems

    Mucopolysaccharidosis (MPS) IIIB is an autosomal recessive disorder caused by a defect in alpha-N-acetylglucosaminidase (NAGLU), a lysosomal enzyme involved in the degradation of heparan sulphate. Dysfunctional NAGLU gives rise to a clinical phenotype of severe and progressive mental retardation, …

    uvic Repository record for The expression of alpha-N-acetylglucosaminidase in two heterologous gene expression systems (opens in a new tab)

  13. Improving CNS Delivery of Genistein for the Treatment of Sanfilippo Syndrome

    … syndrome or mucopolysaccharidosis type III (MPS III), a type of lysosomal storage disease, is a rare genetic disorder inherited in an autosomal recessive manner. Individuals affected by this disease lack the ability to produce one of the four enzymes responsible for the lysosomal degradation …

    houston Repository record for Improving CNS Delivery of Genistein for the Treatment of Sanfilippo Syndrome (opens in a new tab)

  14. Characterization of a murine model of mucopolysaccharidosis type IIID: A knockout model

    <p>The Mucopolysaccharidoses (MPS) are a class of lysosomal storage disorders, characterized by the primary lysosomal storage of either single or multiple species of glycosaminoglycan (GAG) which leads to cell, tissue, and organ dysfunction. This is manifested clinically by either bone/connective …

    iastate Repository record for Characterization of a murine model of mucopolysaccharidosis type IIID: A knockout model (opens in a new tab)

  15. História natural das mucopolissacaridoses : uma investigação da trajetória do paciente desde o nascimento até o diagnóstico

    Mucopolissacaridoses (MPS) são um grupo de doenças metabólicas caracterizadas pelo acúmulo intralisossomal de glicosaminoglicanos. O objetivo deste trabalho foi investigar a trajetória dos pacientes brasileiros com MPS desde o nascimento até o seu diagnóstico. Para tanto, foram realizadas …

    brazil-ufrgs Repository record for História natural das mucopolissacaridoses : uma investigação da trajetória do paciente desde o nascimento até o diagnóstico (opens in a new tab)

  16. Mucopolissacaridoses : um estudo abrangente sobre a epidemiologia da doença no Brasil

    Introdução: As mucopolissacaridoses (MPS) são doenças raras causadas pela deficiência de enzimas lisossômicas responsáveis pela degradação dos glicosaminoglicanos. São doenças graves, crônicas e progressivas. Embora existam diversos estudos disponíveis na literatura médica sobre a frequência das …

    brazil-ufrgs Repository record for Mucopolissacaridoses : um estudo abrangente sobre a epidemiologia da doença no Brasil (opens in a new tab)